中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

310 records (took 0.029 seconds)

    Spiroindoline compound, and medicinal agent comprising same
    241.
    发明授权
    Spiroindoline compound, and medicinal agent comprising same 有权
    螺二氢吲哚化合物和包含其的药剂

    公开(公告)号：US08921576B2

    公开(公告)日：2014-12-30

    申请号：US14351914

    申请日：2012-10-18

    Applicant: Kowa Company, Ltd.

    Inventor： Takahisa Ogamino ,  Yukiyoshi Yamazaki ,  Shin Tanikawa ,  Ayumu Okuda ,  Tomoaki Fukuda ,  Okihisa Tokuda ,  Yoshiharu Miyake ,  Shinsuke Itoh ,  Hiroyuki Ishiwata

    IPC: C07D487/10 ,  C07D519/00

    CPC classification number: C07D487/10 ,  C07D519/00

    Abstract: The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic β-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes.A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt: [wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group; R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, a halo C1-6 alkyl group, a C6-10 aryl group, a cyano group, a C1-6 alkyl group optionally having a substituent, a C2-6 alkenyl group optionally having a substituent, etc.; R3 represents a hydrogen atom, a C1-6 alkyl group optionally having a substituent, etc.; and R4 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally having a substituent, etc.]

    Abstract translation: 本发明提供如下所示的由通式（1）表示的新化合物，其在肝脏和胰腺细胞中具有葡萄糖激酶活化作用，并且其可用作预防和/或治疗疾病引起的药物 通过高血糖症，如糖尿病。 由通式（1）表示的螺二氢吲哚化合物或其盐或化合物或其盐的溶剂合物：[其中环A表示含氮5-10元杂芳基; R 1和R 2相同或不同，各自表示氢原子，卤素原子，卤代C 1-6烷基，C 6-10芳基，氰基，任选具有取代基的C 1-6烷基 任选具有取代基的C 2-6烯基等; R3表示氢原子，任选具有取代基的C1-6烷基等; R4代表氢原子，卤原子，任选具有取代基的C1-6烷基等]

    SOLID COMPOSITION CONTAINING CATECHINS
    242.
    发明申请
    SOLID COMPOSITION CONTAINING CATECHINS 审中-公开
    含有固体成分的CATECHINS

    公开(公告)号：US20140350094A1

    公开(公告)日：2014-11-27

    申请号：US14284779

    申请日：2014-05-22

    Applicant: UMEKEN CO., LTD. ,  KOWA COMPANY, LTD.

    Inventor： Kazuhiro Tanie ,  Mikio Yokoyama ,  Toru Yuasa

    IPC: A61K31/353 ,  A61K47/10

    CPC classification number: A61K31/353 ,  A61K9/2018

    Abstract: A solid composition which contains a large amount of catechins and has solved problems concerning quality and producibility for exerting useful action and effects derived from catechins. The solid composition contains catechins and glycerol.

    Abstract translation: 含有大量儿茶素的固体组合物，并解决了产生儿茶素的有用作用和效果的质量和生产性问题。 固体组合物含有儿茶素和甘油。

    NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME
    243.
    发明申请
    NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME 有权
    新型螺旋体复合物和包含其的药物

    公开(公告)号：US20140309207A1

    公开(公告)日：2014-10-16

    申请号：US14351914

    申请日：2012-10-18

    Applicant: KOWA COMPANY, LTD.

    Inventor： Takahisa Ogamino ,  Yukiyoshi Yamazaki ,  Shin Tanikawa ,  Ayumu Okuda ,  Tomoaki Fukuda ,  Okihisa Tokuda ,  Yoshiharu Miyake ,  Shinsuke Itoh ,  Hiroyuki Ishiwata

    IPC: C07D487/10 ,  C07D519/00

    CPC classification number: C07D487/10 ,  C07D519/00

    Abstract: The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic β-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes.A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt: [wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group; R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, a halo C1-6 alkyl group, a C6-10 aryl group, a cyano group, a C1-6 alkyl group optionally having a substituent, a C2-6 alkenyl group optionally having a substituent, etc.; R3 represents a hydrogen atom, a C1-6 alkyl group optionally having a substituent, etc.; and R4 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally having a substituent, etc.]

    Abstract translation: 本发明提供如下所示的由通式（1）表示的新化合物，其在肝脏和胰腺细胞中具有葡萄糖激酶活化作用，并且其可用作预防和/或治疗疾病引起的药物 通过高血糖症，如糖尿病。 由通式（1）表示的螺二氢吲哚化合物或其盐或化合物或其盐的溶剂合物：[其中环A表示含氮5-10元杂芳基; R 1和R 2相同或不同，各自表示氢原子，卤素原子，卤代C 1-6烷基，C 6-10芳基，氰基，任选具有取代基的C 1-6烷基 任选具有取代基的C 2-6烯基等; R3表示氢原子，任选具有取代基的C1-6烷基等; R4代表氢原子，卤原子，任选具有取代基的C1-6烷基等]

    1-ACYL-4-(PHENOXY, BENZYLOXY, OR PHENYLAMINO)-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES
    246.
    发明申请
    1-ACYL-4-(PHENOXY, BENZYLOXY, OR PHENYLAMINO)-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES 审中-公开
    1-乙酰基-4-（苯氧基，苯甲酰基或苯基）-1,2,3,4-四氢喹啉衍生物

    公开(公告)号：US20130172345A1

    公开(公告)日：2013-07-04

    申请号：US13770175

    申请日：2013-02-19

    Applicant: KOWA COMPANY, LTD.

    Inventor： Masanori Ashikawa ,  Junya Tagashira ,  Akiyasu Koketsu ,  Toshiharu Morimoto ,  Tatsuaki Nishiyama ,  Satoshi Goda ,  Masaki Yamabi ,  Takeshi Doi ,  Hiroyuki Ishiwata

    IPC: C07D215/48 ,  C07D413/12

    CPC classification number: C07D215/48 ,  A61K31/47 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  C07D215/22 ,  C07D215/44 ,  C07D413/04 ,  C07D413/12

    Abstract: Disclosed is a low-molecular-weight compound having an EPO production-promoting activity and/or a hemoglobin expression-enhancing activity. Specifically disclosed is an EPO production promoter and/or a hemoglobin expression enhancer comprising a 1-acyl-4-(phenoxy, benzyloxy or phenylamino)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by the general formula (1); [wherein R1, R2, R2′, R3 and R3′ independently represent a hydrogen atom, a C1-6 alkyl group, or the like; R4, R5, R6, R7, R8, R9 and R16 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or the like; A represents N—R11 or an oxygen atom; R11 represents a hydrogen atom, a C1-6 alkyl group, or the like; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.

    Abstract translation: 公开了具有EPO生产促进活性和/或血红蛋白表达增强活性的低分子量化合物。 具体公开的是EPO生产促进剂和/或血红蛋白表达增强剂，其包含1-酰基-4-（苯氧基，苄氧基或苯基氨基）-1,2,3,4-四氢喹啉衍生物，更具体地是由通式 公式1）; [其中R1，R2，R2'，R3和R3'独立地表示氢原子，C1-6烷基等; R4，R5，R6，R7，R8，R9和R16独立地表示氢原子，卤素原子，C1-6烷基等; A表示N-R11或氧原子; R 11表示氢原子，C 1-6烷基等; n表示0或1的整数]，四氢喹啉化合物的盐或四氢喹啉化合物或其盐的溶剂合物。

    THREE-DIMENSIONAL MEASUREMENT DEVICE
    249.
    发明申请
    THREE-DIMENSIONAL MEASUREMENT DEVICE 有权

    公开(公告)号：US20240384984A1

    公开(公告)日：2024-11-21

    申请号：US18564801

    申请日：2022-03-08

    Applicant: Kowa Company, Ltd.

    Inventor： Jun TAKEDA

    IPC: G01B11/25

    Abstract: To perform three-dimensional measurement of an object with high accuracy, a dot pattern is generated by a determination process of determining a reference position according to a rule defined by a Poisson disk sampling algorithm, a selection process of selecting one of a plurality of arrangement patterns indicating at least one or more dot arrangements, an arrangement process of arranging dots based on the arrangement pattern selected for the reference position, and an iterative process of performing the above processes a plurality of times, a projection device is controlled to project projection light including the dot pattern onto the object, an image capturing device is controlled to image-capture the object onto which the projection light is projected from two directions to acquire two captured images, parallax information is calculated about the acquire two captured images, and a three-dimensional shape of the object is specified based on the calculated parallax information.

Patent Agency Ranking